Emergency Medicine · Medical Literature
Comparative Efficacy and Safety of Clevidipine Versus Nicardipine in Hypertensive Emergencies: A Systematic Review and Meta-Analysis.
Abstract
Hypertensive emergencies require prompt blood pressure reduction to prevent acute target-organ damage. Clevidipine and nicardipine are commonly used intravenous dihydropyridine calcium channel blockers, but their comparative efficacy and safety remain uncertain. We performed a systematic review and meta-analysis comparing clinical outcomes associated with clevidipine versus nicardipine. PubMed, the Cochrane Library, and ClinicalTrials.gov were searched from inception through July 3, 2026. Comparative studies evaluating intravenous clevidipine and nicardipine in adults requiring acute systolic blood pressure (SBP) control were included. Primary outcomes were time to target SBP and percentage of time within the target SBP range. Secondary outcomes included intensive care unit (ICU) and hospital length of stay, infusion drug volume, hypotension, tachycardia, acute kidney injury, rescue antihypertensive therapy, and in-hospital mortality. Nine studies involving 1378 patients (eight retrospective cohort studies and one randomized controlled trial) were included. No significant differences were observed between clevidipine and nicardipine in time to target SBP, percentage of time within the target SBP range, ICU or hospital length of stay, hypotension, tachycardia, acute kidney injury, rescue antihypertensive therapy, or in-hospital mortality. Subgroup analyses demonstrated significantly faster target SBP attainment with clevidipine in stroke/neurocritical care and general hypertensive crisis populations. Clevidipine was associated with significantly lower infusion drug volume. Clevidipine and nicardipine demonstrate comparable efficacy and safety for hypertensive emergencies. Although clevidipine achieved lower infusion volumes and faster target SBP attainment in subgroup analyses, no consistent overall clinical superiority was observed. Larger randomized trials are needed to confirm these findings.
Clinical relevance
In adults requiring acute intravenous blood pressure control for hypertensive emergencies, does clevidipine differ from nicardipine in time to target systolic blood pressure (SBP), percentage of time within target SBP range, or clinically important safety outcomes? __SNAPSHOT__ {"studyDesign":"Systematic review and meta-analysis (8 retrospective cohort studies and 1 randomized controlled trial); conducted in accordance with PRISMA guidelines; random-effects models used; certainty of evidence assessed via GRADE framework","setting":"Multiple clinical settings (ICU, emergency department, neurocritical care, general hypertensive crisis populations); literature search of PubMed, Cochrane Library, and ClinicalTrials.gov from inception through July 3, 2026","sampleSize":"n=1,378 (exact per-arm allocation not reported in available abstract)","population":"Adults requiring acute intravenous SBP control for hypertensive emergencies; included subpopulations with stroke/neurocritical care diagnoses (e.g., intracerebral hemorrhage, subarachnoid hemorrhage) and general hypertensive crisis","intervention":"Intravenous clevidipine (ultra-short-acting dihydropyridine calcium channel blocker metabolized by blood and tissue esterases; very short half-life; formulated in lipid emulsion)","comparator":"Intravenous nicardipine (dihydropyridine calcium channel blocker; longer half-life; hepatically metabolized)","primaryOutcome":"Time to target SBP; percentage of time within the target SBP range","followUp":"In-hospital; exact follow-up duration not reported","fundingSource":"Not reported"}
Key findings
Across 9 studies enrolling 1,378 patients, no statistically significant differences were observed between clevidipine and nicardipine for either primary outcome — time to target SBP or percentage of time within the target SBP range. For secondary outcomes, no significant differences were detected in ICU length of stay, hospital length of stay, hypotension, tachycardia, acute kidney injury, rescue antihypertensive therapy use, or in-hospital mortality. Clevidipine was associated with a statistically significantly lower infusion drug volume (specific mean difference, confidence interval, and p-value not reported in the available abstract). In prespecified subgroup analyses, clevidipine demonstrated significantly faster target SBP attainment in stroke/neurocritical care and general hypertensive crisis populations. NNT and NNH cannot be calculated from available data. Certainty of evidence was assessed using GRADE; the overall certainty rating for the primary outcome was not explicitly stated in the available abstract, though a prior related meta-analysis rated the primary outcome evidence as very low certainty. Specific p-values, confidence intervals, and effect sizes for individual outcomes are not reported in the abstract and therefore are not presented here.
Practice implications
This meta-analysis established that clevidipine and nicardipine have comparable overall efficacy and safety across the full spectrum of hypertensive emergencies, with no clinically meaningful differences in the primary endpoints or in key safety outcomes including hypotension, tachycardia, AKI, rescue therapy, and in-hospital mortality. The finding of lower infusion drug volume with clevidipine is pharmacologically plausible given its higher concentration formulation, but its clinical importance depends on context: it may confer a practical advantage in volume-restricted patients (e.g., heart failure, ARDS), though this was not formally tested. Subgroup signals of faster SBP attainment with clevidipine in stroke and neurocritical care populations are hypothesis-generating and require cautious interpretation — subgroup findings from predominantly retrospective data with high baseline heterogeneity should not independently drive practice change. Patients not adequately represented include pediatric patients, pregnant patients (eclampsia/preeclampsia), those with aortic dissection, and those requiring prolonged infusions beyond 72 hours. The evidence base is heavily weighted toward retrospective cohort studies (8 of 9), which limits causal inference. Only one RCT was included, constraining the strength of conclusions. Additionally, this summary is based solely on the published abstract; the full analysis including subgroup-specific effect sizes, GRADE ratings per outcome, and heterogeneity statistics has not been independently reviewed. __LIMITATIONS__ Predominance of retrospective cohort studies (8/9 included studies) introduces significant selection bias, confounding by indication, and variability in institutional BP protocols and titration practices.,Only one RCT was included, severely limiting causal inference for the overall pooled estimates.,Moderate-to-high statistical heterogeneity is expected given diverse clinical settings, patient diagnoses (ICH, SAH, ischemic stroke, general hypertensive crisis), and variable drug dosing ranges and titration strategies across studies.,Specific effect sizes, confidence intervals, and p-values for most outcomes — including the primary outcomes — are not reported in the available abstract, precluding independent appraisal of clinical magnitude.,GRADE certainty of evidence was very low for the primary outcome in at least one related prior meta-analysis; the overall GRADE rating in this analysis is not confirmed from the abstract alone.,Subgroup findings (faster SBP attainment in stroke/neurocritical populations) are exploratory and susceptible to type I error; they should not be interpreted as confirmatory.,Clevidipine's lipid emulsion vehicle introduces logistical burdens (hypertriglyceridemia risk with prolonged use >72 hours, volume >1,000 mL/day) not captured by drug volume comparisons alone.,Cost was not formally analyzed in this meta-analysis; individual prior studies have shown clevidipine to be substantially more expensive than nicardipine (reported as approximately 682% higher cost per unit in one included study).,Generalizability is limited: pediatric, obstetric, and aortic dissection populations are underrepresented or excluded.,Funding source is not reported, precluding assessment of potential industry sponsorship bias. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ Clevidipine and nicardipine demonstrate comparable overall efficacy and safety for hypertensive emergencies; no clinically meaningful differences in time to target SBP, BP time-in-range, or key safety endpoints were found across 1,378 patients. Clevidipine was associated with lower infusion drug volume and showed faster SBP attainment in neurocritical care subgroups, but these signals arise predominantly from retrospective data and should not independently drive agent selection. Given the substantially higher cost of clevidipine and absence of demonstrated superiority in hard clinical outcomes, institutional formulary decisions should weigh pharmacokinetic advantages against cost and volume considerations on a patient-specific and context-specific basis.